Volume 29, 1985, Numbers 1–3

CONTENTS

Number 1

	PAGE
Antipyretics: *C. G. Van Arman, D. A. J. Armstrong and D. H. Kim*	1
Physiologic pharmacokinetic models and interanimal species scaling: *M. Rowland*	49
Perspectives for gene therapy: Inserting new genetic information into mammalian cells by physical techniques and viral vectors: *M. J. Cline*	69
Surgical intervention in atherosclerosis: Partial ileal bypass and the program on surgical control of the hyperlipidemias (POSCH): *H. Buchwald, L. Fitch and R. L. Varco*	93
Combination chemotherapy, directed at the components of the nucleoside diphosphate reductase: *J. G. Cory and P. Chiba*	111
Praziquantel: Mechanisms of anti-schistosomal activity: *P. Andrews*	129

Number 2

Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man: *M. N. Cayen*	157
The role of cellular oncogenes in cancers of non-viral etiology: *M. P. Goldfarb*	205
Autonomic mechanisms regulating myocardial contractility in conscious animals: *A. M. Fujii and S. F. Vatner*	221
Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives: *H. L. Elford and B. van't Riet*	239
Aluminum toxicology and the aluminum-containing medications: *A. Lione*	255

Number 3

Inhibitors of picornavirus uncoating as antiviral agents: *G. D. Diana, M. J. Otto and M. A. McKinlay*	287
Purification of the interferons: *S. Pestka and S. J. Tarnowski*	299
Modern β-lactam antibiotics: *R. B. Sykes, D. P. Bonner and E. A. Swabb*	321
The influence of snake venom enzymes on blood coagulation: *F. Kornalík*	353
Is the mammalian ribonucleotide reductase really like *Escherichia coli*'s ribonucleotide reductase?: *J. F. Whitfield and T. Youdale*	407